NasdaqGM - Nasdaq Real Time Price USD

Veracyte, Inc. (VCYT)

46.32 -13.46 (-22.52%)
At close: July 31 at 4:00:00 PM EDT
46.09 -0.23 (-0.50%)
After hours: July 31 at 7:54:12 PM EDT
Trade VCYT on Coinbase
VCYT Q2 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for VCYT
  • Previous Close 59.78
  • Open 48.77
  • Bid 36.00 x 200
  • Ask 56.26 x 200
  • Day's Range 43.52 - 50.10
  • 52 Week Range 23.35 - 60.91
  • Volume 5,991,801
  • Avg. Volume 1,338,650
  • Market Cap (intraday) 3.696B
  • Beta (5Y Monthly) 1.93
  • PE Ratio (TTM) 33.09
  • EPS (TTM) 1.40
  • Earnings Date Jul 30, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 58.60

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

www.veracyte.com

755

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 7/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VCYT
10.02%
S&P 500 (^GSPC)
9.41%

1-Year Return

VCYT
97.02%
S&P 500 (^GSPC)
18.15%

3-Year Return

VCYT
68.74%
S&P 500 (^GSPC)
63.21%

5-Year Return

VCYT
3.95%
S&P 500 (^GSPC)
70.40%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 139.07M
Earnings 28.71M

Q3

FY25

Q4

FY25

Q1

FY26

0
50M
100M
 

Analyst Insights

View More

Analyst Price Targets

45.00
58.60 Average
46.32 Current
70.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 7/31/2026
Analyst Needham
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 57 -> 69
 

Statistics

View More

Valuation Measures

Annual
As of 7/31/2026
  • Market Cap

    3.69B

  • Enterprise Value

    3.24B

  • Trailing P/E

    32.99

  • Forward P/E

    26.88

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.70

  • Price/Book (mrq)

    2.65

  • Enterprise Value/Revenue

    5.77

  • Enterprise Value/EBITDA

    25.72

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.37%

  • Return on Assets (ttm)

    3.95%

  • Return on Equity (ttm)

    8.77%

  • Revenue (ttm)

    561.9M

  • Net Income Avi to Common (ttm)

    114.48M

  • Diluted EPS (ttm)

    1.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    485.23M

  • Total Debt/Equity (mrq)

    2.89%

  • Levered Free Cash Flow (ttm)

    104.15M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

46.32 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Lowering target price to $62.00

    Veracyte Inc has an Investment Rating of BUY; a target price of $62.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.

    Rating
    Price Target
     
  • Raising target price to $66.00

    Veracyte Inc has an Investment Rating of BUY; a target price of $66.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.

    Rating
    Price Target
     
  • Raising target price to $63.00

    Veracyte Inc has an Investment Rating of BUY; a target price of $63.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.

    Rating
    Price Target
     
  • Lowering target price to $62.00

    Veracyte Inc has an Investment Rating of BUY; a target price of $62.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.

    Rating
    Price Target
     

People Also Watch